TSX:VPH - Post Discussion
Post by
Sandles on Jun 08, 2020 12:44pm
launches materially accretive to our revenues & profitabily
Good news today, soft tissue sarcoma dtug moving according to plan.
“With the receipt of Health Canada’s approval, Valeo can now assume the commercialization of Yondelis® in Canada. Yondelis® is an important treatment option for patients with soft tissue sarcoma and represents a key addition to our specialty product portfolio”, said Steve Saviuk, Valeo’s President and CEO. “Yondelis® is the first of five product approvals and launches that we anticipate over the second half of the year. We expect that these launches will be materially accretive to our revenues and profitability”. https://www.valeopharma.com/newsroom/
Be the first to comment on this post